^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MK-4830
i
Other names: MK-4830, MK 4830, MK4830
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Agenus, Merck (MSD), Xoma
Drug class:
ILT-4 inhibitor
Related drugs:
14d
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) (clinicaltrials.gov)
P1/2, N=110, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
Enrollment closed
|
Lenvima (lenvatinib) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A) • raludotatug deruxtecan (DS-6000)
3ms
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) (clinicaltrials.gov)
P1/2, N=110, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: May 2026 --> Dec 2029
Trial primary completion date
|
Lenvima (lenvatinib) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A) • raludotatug deruxtecan (DS-6000)
3ms
KEYMAKER-U06 substudy 06B: A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (clinicaltrials.gov)
P1/2, N=230, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Nov 2026 --> Jun 2027
Trial primary completion date
|
Keytruda (pembrolizumab) • paclitaxel • Lenvima (lenvatinib) • irinotecan • dexamethasone • Jiataile (sacituzumab tirumotecan) • MK-4830
6ms
KEYMAKER-U06 substudy 06A: A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) (clinicaltrials.gov)
P1/2, N=90, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
Trial completion
|
Keytruda (pembrolizumab) • paclitaxel • Lenvima (lenvatinib) • irinotecan • MK-4830 • favezelimab/pembrolizumab (MK-4280A)
7ms
KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) (clinicaltrials.gov)
P2, N=102, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • MK-0482 • MK-4830
8ms
KEYMAKER-U02 Substudy 02C: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) (clinicaltrials.gov)
P1/2, N=146, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | N=90 --> 146
Trial completion • Enrollment change
|
Vesanoid (tretinoin) • vibostolimab (MK-7684) • Cavatak (gebasaxturev) • MK-4830 • favezelimab/pembrolizumab (MK-4280A)
8ms
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) (clinicaltrials.gov)
P1, N=470, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2)
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • Lenvima (lenvatinib) • pemetrexed • MK-4830
10ms
KEYMAKER-U02 Substudy 02C: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) (clinicaltrials.gov)
P1/2, N=90, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Apr 2030 --> Oct 2025 | Trial primary completion date: Apr 2030 --> Oct 2025
Trial completion date • Trial primary completion date
|
Vesanoid (tretinoin) • vibostolimab (MK-7684) • Cavatak (gebasaxturev) • MK-4830 • favezelimab/pembrolizumab (MK-4280A)
11ms
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) (clinicaltrials.gov)
P2, N=126, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
Trial completion
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • Lenvima (lenvatinib) • etoposide IV • MK-4830
11ms
KEYMAKER-U06 substudy 06B: A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (clinicaltrials.gov)
P1/2, N=200, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Sep 2028 --> Apr 2029
Trial completion date
|
Keytruda (pembrolizumab) • paclitaxel • Lenvima (lenvatinib) • irinotecan • dexamethasone • Jiataile (sacituzumab tirumotecan) • MK-4830
12ms
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) (clinicaltrials.gov)
P2, N=128, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | Trial completion date: Feb 2032 --> May 2025 | Trial primary completion date: Feb 2032 --> Apr 2025
Trial completion • Trial completion date • Trial primary completion date
|
Keytruda (pembrolizumab) • MK-0482 • MK-4830
1year
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) (clinicaltrials.gov)
P2, N=302, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2027 --> Apr 2026 | Trial primary completion date: Jun 2026 --> May 2025
Trial completion date • Trial primary completion date • Mismatch repair • MSI-H • dMMR
|
MSI (Microsatellite instability)
|
MSI-H/dMMR • RAS wild-type
|
Keytruda (pembrolizumab) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A) • vibostolimab/pembrolizumab (MK-7684A)
Share via
